Coverage at a glance
| Indication | Coverage |
|---|---|
| Obesity / weight management | Not covered |
Prior authorization: the plan reviews the prescription before it pays.
Yes on some plans. BCBSIL runs its drug benefit through Prime Therapeutics, its pharmacy benefit manager. Weight-loss and GLP-1 coverage is an optional benefit, and each employer group chooses to add it or leave it out. Many plans leave weight-loss drugs out of the benefit entirely. Where an employer did add it, Wegovy is covered once the plan signs off. The usual bar is a BMI of 30 or higher, or 27 or higher with a weight-related condition. You also need a written record of diet and lifestyle effort. Check with your plan or your employer before you assume weight-loss drugs are in. This answer covers commercial plans that are not Medicare.
Source: Pharmacy Benefit for GLP-1 and/or Anti-Obesity Drug Therapy. Checked August 28, 2026.
Where your plan lists it. The Performance Annual Drug List, updated June 1, 2026, marks Wegovy P+ for Blue Advantage HMO and Blue Advantage Value Choice HMO members. P is the list's preferred brand code and the plus sign means coverage depends on your group. Prior authorization applies, and the quantity limit changes with the dose. Source: Blue Cross and Blue Shield of Illinois Performance Annual Drug List. Checked September 6, 2026.
What it costs once they say yes. With commercial insurance the manufacturer savings card takes Wegovy to as little as $25 a month. Your plan sets the copay before the card applies. What Wegovy costs with your plan.
This varies by plan. BCBSIL runs weight-loss and GLP-1 coverage through Prime Therapeutics. It sells that coverage to employer groups as three optional programs. They are GLP-1 New to Therapy, GLP-1 30-Day Max, and Anti-Obesity 30-Day Max. BCBSIL says the categories and medications included may vary according to employer group selections. So Wegovy is covered only where the employer bought the coverage. A plan that did not buy it treats weight-loss drugs as a benefit exclusion, not a medical-necessity denial.
If the weight-loss exclusion above applies to you, you are paying for this yourself.
Coverage by indication
| BMI threshold | 30, or 27 with a weight-related condition |
| Step therapy | Varies by plan. Some plans require a written record of earlier weight-loss drugs |
What the prior authorization needs:
- Coverage applies only where the employer group bought the GLP-1 or anti-obesity drug benefit through Prime Therapeutics. Many plans leave weight-loss drugs out entirely.
- Where the benefit is bought, the plan has to sign off. BCBSIL runs that through its weight management program with Prime Therapeutics.
- A BMI of 30 or higher. A BMI of 27 or higher works with a weight-related condition. That is the standard weight-management bar, and BCBSIL does not publish a criteria document of its own.
- A written record that you cut calories and moved more, or that you took part in a lifestyle or behavioral weight-management program.
- To renew it you usually need to have lost at least 5% of your starting weight.
Source: Pharmacy Benefit for GLP-1 and/or Anti-Obesity Drug Therapy. The plan's own bulletin to providers. Lower confidence: the policy file would not open at the payer's own address, so the policy number and rules were checked against a second source.
Ozempic, Mounjaro and Rybelsus on BCBS Illinois plans
Ozempic, Mounjaro and Rybelsus are approved for type 2 diabetes, not weight loss.
Does BCBS Illinois cover Ozempic?
Yes, with prior approval. BCBS Illinois pays for Ozempic once your prescriber gets the plan to sign off.
BCBS Illinois covers Ozempic for type 2 diabetes on its 2026 commercial drug lists. It sits there as a preferred brand. The plan has to sign off, and a quantity limit of one pen every 28 days applies. Approval needs a documented type 2 diabetes diagnosis, and it runs 12 months before it has to be renewed. BCBSIL does not cover Ozempic for weight loss, because the FDA approved it for type 2 diabetes only. Wegovy is the semaglutide for weight loss. It is a separate product at a higher dose, with rules of its own.
Checked August 27, 2026.
What BCBS Illinois requires for Ozempic
| Step therapy | Not required |
What the prior authorization needs:
- Documented diagnosis of type 2 diabetes
- Prior authorization approved before the pharmacy fills it
- Quantity limit of one pen per 28 days
- Ozempic is a preferred-brand agent, so you do not have to step through another GLP-1 first
- Approval lasts 12 months, then must be renewed
- The type 2 diabetes diagnosis and the 12-month approval both come from the Prime Therapeutics GLP-1 criteria, in force from April 1, 2026.
Source: BCBS Illinois policy 2656-Y. The plan's own covered-drug list.
Does BCBS Illinois cover Mounjaro?
Yes, with prior approval. BCBS Illinois pays for Mounjaro once your prescriber gets the plan to sign off.
BCBS Illinois covers Mounjaro (tirzepatide) for type 2 diabetes on its 2026 commercial drug list. The plan has to sign off, and quantity limits apply. The sign-off criteria require that the patient has already tried a diabetes drug, so a first-line drug like metformin usually comes first. BCBSIL will not cover Mounjaro for weight loss. Zepbound is the weight-loss tirzepatide. BCBSIL lists it separately, and covers it only where the employer group bought a weight-loss benefit.
Checked August 27, 2026.
What BCBS Illinois requires for Mounjaro
| Step therapy | Required |
What the prior authorization needs:
- Prior authorization required. The GLP-1 agonists program covers Mounjaro when it is used per FDA-approved labeling and dosing.
- Step therapy applies. You have to have tried another drug for diabetes first, usually metformin, before Mounjaro.
- A quantity limit of 4 pens per 28 days for the 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg strengths. And 4 pens per 180 days for the 2.5 mg starter strength. Both come from the July 2026 Multi-Tier Basic Annual drug list.
- Listed as a covered brand on the July 2026 drug list. What you pay depends on how the member's benefit is built. That list prints no tier per drug, and it leaves non-preferred drugs off.
- Not covered for weight loss. Zepbound is the weight-loss tirzepatide. It is listed separately, it needs its own sign-off, and it is covered only where the employer bought an anti-obesity benefit.
Source: BCBS Illinois policy 23466.0726. The plan's own prior-authorization policy.
Does BCBS Illinois cover Rybelsus?
Yes, with prior approval. BCBS Illinois pays for Rybelsus once your prescriber gets the plan to sign off.
BCBS Illinois covers Rybelsus for type 2 diabetes once the plan signs off. Prime Therapeutics, the pharmacy benefit manager for BCBS Illinois, runs that sign-off. Approval needs a documented type 2 diabetes diagnosis, and an earlier trial of another drug for diabetes. Quantity limits apply. Rybelsus is not covered for weight loss, because the FDA approved it for type 2 diabetes only. Wegovy is the semaglutide for weight loss, and BCBS Illinois lists it separately with a sign-off of its own.
What BCBS Illinois requires for Rybelsus
| Step therapy | Required |
What the prior authorization needs:
- Documented diagnosis of type 2 diabetes
- An earlier trial of another drug for diabetes, per the BCBS Illinois GLP-1 agonist criteria
- Quantity limits apply per the July 2026 Multi-Tier Basic Annual Drug List (form 2656-1N IL): 30 tablets per 30 days for the 7 mg and 14 mg doses, and 30 tablets per 180 days for the 3 mg starting dose
Source: BCBS Illinois policy 23466.0726. The plan's own prior-authorization policy.
Recent change: On the July 2026 drug list, Rybelsus is listed and covered for type 2 diabetes once the plan signs off.
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it. Plans that approve reassess at renewal, so know your long-term maintenance dose before you start.
- Browse the prior-authorization letter library for a template that matches your plan and indication.
- Read why plans say no and the four ways to appeal in the GLP-1 insurance guide.
- Your plan may treat another GLP-1 differently. The BCBS Illinois coverage check lists all 5, with the source for each.
- If the plan denies it, the appeal letter library has a template for each reason a plan gives. That covers the peer-to-peer call with a plan doctor, the Level 1 and Level 2 appeals inside the plan, and the outside review that follows them.
- Call the number on your insurance card and ask whether your specific plan includes the weight-management drug benefit before you submit.
- If your plan does not cover the indication you need, compare cash prices in the cost guide or check whether a clinical trial near you fits. Neither one goes through your insurer. Clinical trials cost nothing and many pay you for your time.
What it costs without insurance
The programs below bill you directly.
Frequently asked questions
Does BCBS Illinois cover Wegovy?
Yes on some plans. BCBSIL runs its drug benefit through Prime Therapeutics, its pharmacy benefit manager. Weight-loss and GLP-1 coverage is an optional benefit, and each employer group chooses to add it or leave it out. Many plans leave weight-loss drugs out of the benefit entirely. Where an employer did add it, Wegovy is covered once the plan signs off. The usual bar is a BMI of 30 or higher, or 27 or higher with a weight-related condition. You also need a written record of diet and lifestyle effort. Check with your plan or your employer before you assume weight-loss drugs are in. Policy checked August 2026.
Why might BCBS Illinois deny Wegovy even if I meet the criteria?
BCBSIL runs weight-loss and GLP-1 coverage through Prime Therapeutics. It sells that coverage to employer groups as three optional programs. They are GLP-1 New to Therapy, GLP-1 30-Day Max, and Anti-Obesity 30-Day Max. BCBSIL says the categories and medications included may vary according to employer group selections. So Wegovy is covered only where the employer bought the coverage. A plan that did not buy it treats weight-loss drugs as a benefit exclusion, not a medical-necessity denial.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Every page here comes from the payer's own policy, a federal law, or KFF's plan research. Each row links its source and gives the date we read it. Some plan files load at the address the payer gives but will not open. We check those against a second source and mark the row lower confidence. Job-based plans also choose whether to add the weight-drug benefit at all, so those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
